Citations

Showing 10 of 107861 citations.

PD-L1 deletion or blockade regulate macrophage antigen presentation and checkpoint molecule surface levels
Waddell, Trinity Q Alaka’i , Dong, Haidong , Roh‐Johnson, Minna , Lancaster, Jessica N. , Waddell, Trinity , Dong, Haidong , Lancaster, Jessica N

Mayo Clinic

No container title available | June 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.23.734016 | PMID 42427499 Get It

Abstract Macrophages in the tumor microenvironment are known to upregulate PD-L1 expression, thereby suppressing T cells through PD-1 ligation. However, the manner in which PD-L1 expression intrinsically impacts macrophages and their immunomodulatory phenotype is less clear. Clarifying this knowledge gap would yield insight into the mechanisms of immunosuppression within the tumor microenvironment. To characterize the macrophage intrinsic role of PD-L1, we used complementary genetic and pharmacological approaches by analyzing primary murine bone marrow-derived macrophages (BMDMs) with complete genetic PD-L1 deletion and wildtype BMDMs treated with anti-PD-L1 blocking antibodies. Macrophages were evaluated across naïve, pro-inflammatory (M1), and tumor conditioned (TCM) polarization states in vitro. Unlike prior reports, neither genetic deletion nor antibody blockade dramatically altered the expression of macrophage polarization markers or in vitro phagocytic capacity. Both conditions consistently reduced surface levels of the M1-associated costimulatory molecule CD80, prompting further analysis of T cell interacting and antigen presenting proteins, in which we revealed disparate effects of genetic deletion and antibody blockade on the surface levels of MHCI, MHCII, PD-1, and PD-L2. These findings suggest that PD-L1 deletion and antibody-mediated blockade contribute to macrophage immune regulatory profiles in distinct manners. This difference supports a model in which PD-L1 functions in macrophages beyond its canonical role as a ligand for PD-1, influencing antigen presentation and checkpoint molecule levels and playing a broader role in immune regulation in the tumor microenvironment.
Diminishing Returns of Novel Autoantibody Discovery in Encephalitis
Takegami, Naoki, Day, Gregory S., Day, Gregory S. , Leypoldt, Frank , Irani, Sarosh R.

Mayo Clinic

JAMA Neurology | June 29, 2026 | Volume: 83 | Issue: 8 | Pages: 719

10.1001/jamaneurol.2026.1659 | PMID 42371641 Get It

This Viewpoint describes a plateau in the discovery of clinically meaningful autoantibodies in autoimmune encephalitis (AE) and suggests efforts that are likely to offer greater benefits to patients living with AE.
One Step Closer to Real-Time Detection of Missed Opportunities for Diagnosis in the ED Using LLMs
Cabrera, Daniel, Bellolio, Fernanda , Cabrera, Daniel

Mayo Clinic

JAMA Network Open | June 29, 2026 | Volume: 9 | Issue: 6 | Pages: e2620947

10.1001/jamanetworkopen.2026.20947 | PMID 42371631 Get It

In Defense of Novel Autoantibody Discovery
Prüss, Harald, Arlt, Friederike A., Dubey, Divyanshu, Prüß, Harald , Arlt, Friederike A. , Höftberger, Romana , Dubey, Divyanshu

Mayo Clinic

JAMA Neurology | June 29, 2026 | Volume: 83 | Issue: 8 | Pages: 721

10.1001/jamaneurol.2026.2027 | PMID 42371614 Get It

This Viewpoint discusses the discovery of numerous neuronal autoantibodies and how autoimmune encephalitis is diagnosed and treated.
Pricing for Oncology Biosimilars
Jensen, Chelsee, Tichy, Eric, Jensen, Chelsee , Tichy, Eric M.

Mayo Clinic

JAMA | June 29, 2026 | Volume: 336 | Issue: 4 | Pages: 346

10.1001/jama.2026.6815 | PMID 42371655 Get It

Clinical Features, Treatment, and Outcomes for Oropharyngeal Adenoid Cystic Carcinoma: A Systematic Review
Hernandez-Herrera, Gabriel A. , Rourk, Katelyn S. , Moore, Eric J. , Price, Daniel L., Tasche, Kendall K. , Price, Katharine A., Abel, Kathryn M. Van , Peraza, Lazaro R. , Lester, Scott C. , Van Abel, Kathryn M , Hernandez Herrera, Gabriel A , Price, Daniel L. , Routman, David M. , Yin, Linda X.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ohn.70319 | PMID 42371638 Get It

Abstract Objective To describe the presenting symptoms, treatment regimens, and outcomes associated with oropharyngeal adenoid cystic carcinoma. Data Sources Ovid MEDLINE(R), Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, and Scopus via Elsevier. Review Methods This review followed the Preferred Reporting Items for Systematic Reviews and Meta‐analyses. A medical librarian conducted the literature search using controlled vocabulary and keywords, with investigator input. Eligible articles were clinical trials and observational studies reporting on clinical features, treatment, or outcomes for oropharyngeal adenoid cystic carcinoma. Results Our search identified 233 unique citations, with 44 articles included covering 195 patients. The female‐to‐male ratio was 1.7:1, and the base of the tongue was the most common subsite (73%). Presenting symptoms were mainly pain/discomfort (n = 31), followed by a palpable mass (n = 19) and dysphagia (n = 12). At diagnosis, 22.3% (29 patients) had positive lymph nodes. Treatment was primarily surgical (n = 102), with definitive radiation therapy used in 58 cases. Disease progression was noted in 86 patients, 36% (n = 31) of whom developed distant metastases—primarily to the lungs (n = 26). Long‐term outcomes (n = 76) showed 3‐ and 5‐year overall survival rates of 71.5% to 100% and 47.6% to 79.0%, and disease‐free survival rates of 54.7% to 70.0% and 21.9% to 44.0%, respectively. Conclusion Among patients with available data, oropharyngeal adenoid cystic carcinoma appeared more common in women and has a predilection for the base of the tongue. However, this finding should be interpreted with caution, given the high proportion of missing data. These tumors appear to carry a higher risk for nodal metastases and may lead to poor outcomes.
Management trends and outcomes of femur fractures in children with cerebral palsy: a systematic review and meta-analysis
Garabedian, Mark, Benaroch, Lee , Charron, Brynn, Carey, Tim, Bartley, D., Thornley, Patrick, Alatassi, Raheef, Charron, Brynn Petras , Alatassi, Raheef , Carey, Tim, Thornley, Patrick

Mayo Clinic

Journal of Pediatric Orthopaedics B | June 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/bpb.0000000000001373 | PMID 42370877 Get It

This review aims to evaluate the treatment and outcomes of femur fractures in children with cerebral palsy (CP). Femur fractures are common in this population because of physiological and mechanical factors. Treatment approaches vary based on functional status and fracture characteristics. Medline, Embase, Central, and Scopus databases were systematically searched for studies investigating outcomes following femur fractures in children aged 0–18 with CP who received surgical or nonsurgical treatment. Primary outcomes were fracture location, ambulatory status, treatment types, and complications. A meta-analysis was conducted when data homogeneity permitted, using mean differences for continuous outcomes and risk ratios for dichotomous outcomes. Of 213 screened articles, seven were included, reporting 335 femur fractures in 258 patients. Most fractures occurred in the distal femur (52%) followed by mid-diaphyseal fractures (32%). Treatment varied by ambulatory status and fracture location, with 60% managed nonoperatively, typically in nonambulatory patients and for distal fractures. Nonoperative treatment, mainly spica casting, showed higher malunion rates (29%) and complications like pressure sores (11%). In contrast, operative treatment, preferred for proximal and mid-diaphyseal fractures, resulted in lower malunion rates in nonambulatory children (7%; P = 0.02) but had risks of postoperative pneumonia (6%) and surgical site infection (13%). Outcomes indicated improved healing and function with operative treatments in ambulatory children. Femur fractures in children with CP require individualized treatments based on the patient’s fracture type and ambulatory status. Future studies should incorporate fracture mitigation metrics, functional outcomes, and caregiver impact to inform optimal patient-centered care.
Reply to “Methodological Challenges in Interpreting SAA ‐Defined Imaging Subgroups in Parkinson's Disease”
Chiu, Shannon , Wang, Wei‐en , Chen, Robin , Adler, Charles H., Mehta, Shyamal H. , Dresler, Sara R. , Armstrong, Melissa J., McFarland, Nikolaus, Okun, Michael S., Vaillancourt, David E., Chiu, Shannon Y , Dresler, Sara R , DeSimone, Jesse C. , Archer, Derek B. , Adler, Charles H. , Armstrong, Melissa J. , McFarland, Nikolaus R. , Okun, Michael S. , Vaillancourt, David E.

Mayo Clinic

Annals of Neurology | June 29, 2026 | Volume: 100 | Issue: 2 | Pages: 440-441

10.1002/ana.78292 | PMID 42370778 Get It

Comparison of blood culture contamination rates with standard practice versus two blood diversion devices at a single institution
Vieni, Casey , Legried, Michele, Mainella, Jill, Bute, Kelly, Backus, Linda, Sampathkumar, Priya , Schuetz, Audrey N. , Patel, Robin , Karon, Brad S. , Patel, Robin , Schuetz, Audrey N , Mainella, Jill M.

Mayo Clinic

Journal of Clinical Microbiology | June 29, 2026 | Volume: 64 | Issue: 8 | Pages: No page available

10.1128/jcm.00085-26 | PMID 42370687 Get It

ABSTRACT Blood culture contamination can lead to false-positive blood culture results, potentially contributing to increased costs and unneeded antibiotic utilization. Initial specimen diversion devices (ISDD) have been proposed to reduce blood culture contamination rates. A single-center, observational study conducted at Mayo Clinic Rochester compared blood culture contamination rates using Steripath or Kurin ISDDs versus standard blood culture collection protocols. Over 255 phlebotomists were trained in the use of the ISDDs, with 31,215 blood cultures, 410 of which were contaminated, collected from adults in the emergency department and inpatient wards. Baseline contamination rates were 1.29%–2.53% with standard collection methods. The Steripath ISDD with direct-to-media inoculation of blood culture bottles (Steripath-DTM) reduced blood culture contamination compared to standard practice (0.34% vs. 1.43%, respectively, P < 0.001). Follow-up studies with the alternative Steripath configuration with an integrated syringe (Steripath-syringe), and then the Kurin ISDD with syringe collection (Kurin-syringe), did not meet the primary endpoint of <0.5% contamination (Steripath-syringe: 1.28%; Kurin-syringe: 1.76%). All three ISDD configurations failed to meet our goal of >75% utilization, with an average measured utilization of 26% for the Steripath-DTM, 26.4% for the Steripath ISDD (combined DTM and syringe) in a follow-up study, and 41.5% in the Kurin study. Additionally, a survey of phlebotomists revealed low staff satisfaction with both Steripath ISDD configurations. Staff reported multiple ergonomic barriers limiting the Steripath ISDD’s utility, which precluded implementation of the Steripath-DTM in routine clinical practice. IMPORTANCE We conducted a very large, real-world study of two blood diversion devices to determine whether either would meet goals for reduced blood culture contamination and a high rate of utilization by phlebotomists.
Distal Agrin ( AGRN ) Congenital Myasthenic Syndrome With Mitochondrial Dysfunction
Oku, Mariana Hiromi Manoel , Selcen, Duygu , Litchy, William J. , Milone, Margherita , Oku, Mariana Manoel , Milone, M , Niu, Zhiyv

Mayo Clinic

European Journal of Neurology | June 29, 2026 | Volume: 33 | Issue: 7 | Pages: No page available

10.1111/ene.70690 | PMID 42367086 Get It

ABSTRACT Background Agrin‐congenital myasthenic syndrome ( AGRN ‐CMS) is a rare, heterogeneous genetic disorder of the neuromuscular transmission that can present from infancy to adulthood. The clinical phenotype includes distal weakness mimicking distal myopathies. Additionally, electromyography and muscle biopsy may demonstrate myopathic features, increasing the diagnostic challenge. Mitochondrial dysfunction has not been reported in the muscle of AGRN ‐CMS patients. Methods We report the clinical, electrophysiological, radiological, myopathological, and genetic findings of a patient with AGRN‐ CMS. Results A 47‐year‐old male presented at age 18 with sudden onset of eyelid ptosis, weakness, and fatigue, followed by dysphagia, dyspnea on exertion, exercise intolerance, and myalgias. Three sisters had similar symptoms. Neurological examination showed lower limb weakness, predominantly affecting the calf muscles with associated atrophy. Tendon reflexes were normal but absent at the ankles. Creatine kinase levels were normal. Electromyography demonstrated myopathic changes in distal muscles with fibrillation potentials in the gastrocnemius. 2 Hz‐Repetitive nerve stimulation of the fibular nerve revealed a 32% decrement in the extensor digitorum brevis without facilitation. Tibialis anterior biopsy showed non‐specific myopathic changes, neurogenic features, and histological evidence of mitochondrial dysfunction, as suggested by the scattered cytochrome c oxidase‐negative fibers. Whole exome sequencing detected a homozygous pathogenic AGRN variant (c.5012G>A, p.Arg1671Gln). No pathogenic or suspected pathogenic variants were detected in muscle mitochondrial DNA or in nuclear genes affecting mitochondrial function. Conclusions This patient expands the pathological spectrum of AGRN ‐CMS to include mitochondrial dysfunction and highlights the importance of low‐frequency repetitive nerve stimulation in the assessment of patients with distal weakness for differentiating myopathies from CMS.